logo
NHS launches new drive to find more people with deadly pancreatic cancer

NHS launches new drive to find more people with deadly pancreatic cancer

Hundreds of GP practices in England are being given extra funding to comb patient records looking for people with the disease, which has the lowest survival rate of all cancers.
GPs and their teams will look for people over 60 who may have signs of the cancer, such as a recent diagnosis of diabetes and sudden weight loss.
Figure suggest that around half of people diagnosed with pancreatic cancer have been diagnosed with type 1 or 2 diabetes recently.
Family doctors taking part in the NHS England pilot will then contact patients and send them for urgent blood tests and CT scans to rule cancer in or out.
Pancreatic cancer can have vague symptoms and is often diagnosed in the late stages.
According to researchers, newly-diagnosed diabetes patients often have similar symptoms as a person with early-stage pancreatic cancer.
This is because the cancer destroys the same insulin-producing cells that are also destroyed in diabetes.
Around 10,500 people in the UK are diagnosed with pancreatic cancer every year and only around one in 20 survive the disease for 10 years or more.
More than half of people die within three months of diagnosis.
For the new three-year pilot, more than 300 GP practices in England will be involved, with all practices up and running by the autumn.
Almost £2 million in targeted funding has been invested to help practices find people most at risk and give patients the best chance of being diagnosed early.
Professor Peter Johnson, NHS national clinical director for cancer, said: 'Pancreatic cancer is responsible for so many deaths because patients don't usually notice symptoms until the cancer is at an advanced stage, which is why we need to find new ways to pick it up.
'Through initiatives like this and the upcoming 10-year health plan, the NHS is determined to go a step further – not just treat people at an advanced stage but to go out into communities and seek people out who might be unwell without any symptoms so we can provide people with the most effective treatment.
'The NHS is seeing and treating more people with cancer than ever, and early diagnosis is key to ensure patients have the best chance of receiving effective treatment.
'If your GP practice identifies you as at risk of pancreatic cancer, I urge you to come forward for testing as soon as possible.'
Health minister Karin Smyth said: 'This targeted approach to identify people at risk of one of the most lethal cancers could give more people a fighting chance and spare the heartbreak of countless families.'
We're delighted to see the Government commit to boosting clinical trials as part of their forthcoming 10 year plan. Clinical trials are a crucial treatment option for people with #PancreaticCancer & improving access to them could be key to driving up treatment & survival rates 🧪 https://t.co/QT1gQvZXR2
— Pancreatic Cancer UK (@PancreaticCanUK) June 16, 2025
Alfie Bailey-Bearfield, head of influencing and health improvement at Pancreatic Cancer UK, said: 'Diagnosing more people with pancreatic cancer earlier, when the disease is most treatable, would make the single biggest difference to improving survival, so we are delighted to see significant further investment from NHS England towards that incredibly important goal.
'We're proud to have been involved in shaping this new case finding pilot, which will support GPs to proactively find people with pancreatic cancer among one of largest groups known to be at increased risk: those aged over 60, with new onset diabetes who have recently lost weight without trying to do so.
'Many of the people who are referred for a CT scan during the pilot will not have pancreatic cancer, but for those that do, the impact could be lifesaving.
'Subject to the pilot's success, we will be calling for this pilot to be expanded across the country to help give more people affected by the deadliest common cancer the very best chance of survival.'
Previous research has shown that people over 50 with a new case of type 2 diabetes have a higher chance of being diagnosed with pancreatic cancer within three years.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mounjaro could help obese people control asthma says study
Mounjaro could help obese people control asthma says study

The Herald Scotland

time36 minutes ago

  • The Herald Scotland

Mounjaro could help obese people control asthma says study

As an estimated 1.5 million people in the UK are now using weight loss drugs. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Recommended reading: 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.' Who is eligible for Mounjaro on the NHS? At the moment, the rules are very strict, and treatment is being rolled out gradually by NHS England. NICE has recommended tirzepatide (Mounjaro) for weight management for eligible adults living with obesity, who also present with other weight-related health problems, including: dyslipidaemia (abnormal fat levels in the blood) hypertension (high blood pressure) obstructive sleep apnoea (when your breathing stops and starts while you sleep) cardiovascular disease (heart and blood vessel disease) type 2 diabetes mellitus Speak to your doctor for more information.

Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help obese people control asthma, study suggests

South Wales Argus

time3 hours ago

  • South Wales Argus

Weight-loss jabs could help obese people control asthma, study suggests

The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help obese people control asthma, study suggests

Rhyl Journal

time4 hours ago

  • Rhyl Journal

Weight-loss jabs could help obese people control asthma, study suggests

The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store